EP 211: Building hope for inherited blindness and deafness with Justin Porcano of Save Sight Now

EP 211: Building hope for inherited blindness and deafness with Justin Porcano of Save Sight Now

by Sano Genetics

Life & Natural Systems Medicine & Health MJCGCongenital diseases and disordersMJCG1Hereditary diseases and disorders
🎙 Sano Genetics 👥 942 📅 November 19, 2025 ⏱ 30 min 👁 28 📄 expert opinion 🧭 2026-08-16
Available in: English (current) Français

Keywords

Usher syndrome type 1Bgene therapyrare disease researchpatient advocacynonprofit

Summary

In this episode of The Genetics Podcast, host Patrick Short interviews Justin Porcano, co-founder and executive director of Save Sight Now, a nonprofit dedicated to finding treatments for Usher syndrome type 1B (USH1B). Justin shares his personal journey after his daughter Leah was diagnosed with USH1B, which causes congenital deafness, vestibular issues, and progressive vision loss. He explains the initial challenges in the field, including the large size of the MYO7A gene, lack of good animal models, and undefined clinical endpoints. Save Sight Now has invested in developing animal models, including a pig model and a non-human primate, and is funding natural history studies to establish endpoints. The conversation covers advances in gene delivery, such as dual AAV approaches and nanoparticles, and the importance of early intervention for hearing and vision. Justin discusses the decision to become an independent nonprofit to have more flexibility and direct collaboration with biotech companies. He emphasizes the need for stronger partnerships between patient organizations and biotech to accelerate research. The episode concludes with plans for the next five years, focusing on extending the therapeutic window and moving toward clinical trials.

186 words

Critical Evaluation

Value of the Information & Strength of the Argument

The podcast provides valuable insights into the challenges and progress in rare disease research, particularly for Usher syndrome type 1B. Justin Porcano’s perspective as a parent and nonprofit leader offers a unique and compelling argument for the importance of patient advocacy in driving research. He clearly articulates the bottlenecks in therapeutic development, such as gene size and lack of animal models, and explains how Save Sight Now is addressing them. The argumentation is logical and well-structured, though it relies primarily on anecdotal evidence and personal experience rather than scientific data. The discussion is informative for those interested in rare disease advocacy and gene therapy, but it lacks depth in technical details and does not provide a comprehensive review of the scientific literature.

Scientific Rigor, Source Quality, Title Accuracy

The podcast demonstrates a reasonable level of scientific rigor, with Justin referencing specific research efforts and collaborations, such as the pig model in Germany and the non-human primate at OHSU. However, the sources cited are not detailed, and the discussion is based on expert opinion rather than peer-reviewed publications. The title accurately reflects the content, focusing on building hope for inherited blindness and deafness through the work of Save Sight Now. The podcast is well-produced and the host asks relevant questions, but the lack of concrete citations and the reliance on personal narrative limit its scientific rigor. No comments were provided for analysis.

240 words

Title / Content Match

The title accurately reflects the content, focusing on building hope for inherited blindness and deafness through the work of Save Sight Now.

Quality & Reliability

7/10

The podcast features an expert interview with a patient advocate and nonprofit leader, providing credible insights into rare disease research and advocacy. However, it lacks peer-reviewed sources and detailed scientific data, and the information is presented from a personal and organizational perspective.

Chapters

Cited Sources

Concurring Sources

  • Save Sight Now — The organization's website provides information about their mission and research initiatives, consistent with the podcast content.

Contribution & Novelties

This podcast offers a unique perspective on rare disease advocacy, highlighting the role of patient organizations in accelerating research. It provides an inside look at the challenges and strategies of a nonprofit focused on Usher syndrome type 1B, including the development of animal models and natural history studies. The discussion on gene delivery approaches, such as dual AAV and nanoparticles, is relevant to the broader gene therapy field. The episode emphasizes the importance of collaboration between patient organizations and biotech companies, which is an often-overlooked aspect of drug development.

Pour aller plus loin :

136 words

Radar Profile

The radar profile shows a balanced performance across all dimensions, with slightly higher scores in information quantity and quality, reflecting the informative nature of the podcast. The technical level is moderate, suitable for a general audience, and the reliability is good, though not based on peer-reviewed sources.

Reliability 7/10